Evaluation of PAX3 genetic variants and nevus number

The presence of a high nevus number is the strongest phenotypic predictor of melanoma risk. Here, we describe the results of a three‐stage study directed at identifying risk variants for the high nevus phenotype. At the first stage, 263 melanoma cases from Barcelona were genotyped for 223 single‐nucleotide polymorphisms (SNPs) in 39 candidate genes. Seven SNPs in the PAX3 gene were found to be significantly associated with nevus number under the additive model. Next, the associations for seven PAX3 variants were evaluated in 1217 melanoma cases and 475 controls from Leeds; and in 3054 healthy twins from TwinsUK. Associations with high nevus number were detected for rs6754024 (P values < 0.01) in the Barcelona and Leeds datasets and for rs2855268 (P values < 0.01) in the Barcelona and the TwinsUK sets. Associations (P values < 0.001) in the opposite direction were detected for rs7600206 and rs12995399 in the Barcelona and TwinsUK sets. This study suggests that SNPs in PAX3 are associated with nevus number, providing support for PAX3 as a candidate nevus gene. Further studies are needed to examine the role of PAX3 in melanoma susceptibility.

[1]  H. Shaw,et al.  A Phosphatidylinositol 3-Kinase–Pax3 Axis Regulates Brn-2 Expression in Melanoma , 2012, Molecular and Cellular Biology.

[2]  K. Brown,et al.  A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma , 2011, Nature.

[3]  C. Kimchi-Sarfaty,et al.  Understanding the contribution of synonymous mutations to human disease , 2011, Nature Reviews Genetics.

[4]  H. Rizos,et al.  Differential PAX3 functions in normal skin melanocytes and melanoma cells. , 2011, Biochemical and biophysical research communications.

[5]  Jeffrey E. Lee,et al.  Genome-wide association study identifies nidogen 1 ( NID1 ) as a susceptibility locus to cutaneous nevi and melanoma risk , 2022 .

[6]  Simon C. Potter,et al.  The Architecture of Gene Regulatory Variation across Multiple Human Tissues: The MuTHER Study , 2011, PLoS genetics.

[7]  Tsun-Po Yang,et al.  Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies , 2010, Bioinform..

[8]  Nicole Soranzo,et al.  IRF4 variants have age-specific effects on nevus count and predispose to melanoma. , 2010, American journal of human genetics.

[9]  M. Eccles,et al.  PAX3 Is extensively expressed in benign and malignant tissues of the melanocytic lineage in humans. , 2010, The Journal of investigative dermatology.

[10]  M. Ziman,et al.  PAX3 Expression in Normal Skin Melanocytes and Melanocytic Lesions (Naevi and Melanomas) , 2010, PloS one.

[11]  J. Barrett,et al.  Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. , 2009, European journal of cancer.

[12]  T. Spector,et al.  Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi , 2009, Nature Genetics.

[13]  Roger L Milne,et al.  Pigmentation‐related genes and their implication in malignant melanoma susceptibility , 2009, Experimental dermatology.

[14]  M. Ziman,et al.  PAX3 across the spectrum: from melanoblast to melanoma , 2009, Critical reviews in biochemistry and molecular biology.

[15]  Andreas Ziegler,et al.  A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes , 2009, International journal of cancer.

[16]  J. Malvehy,et al.  Prevalence Study of Nevi in Children from Barcelona , 2008, Dermatology.

[17]  D. Lang,et al.  Pigmentation PAX‐ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease , 2008, Pigment cell & melanoma research.

[18]  Yinshi Guo,et al.  Inhibition of PAX3 by TGF-beta modulates melanocyte viability. , 2008, Molecular cell.

[19]  A Hofman,et al.  Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study , 2008, The Lancet.

[20]  C. Shea,et al.  PAX3 expression in primary melanomas and nevi , 2008, Modern Pathology.

[21]  Claus Garbe,et al.  Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight. , 2008, Advances in experimental medicine and biology.

[22]  K. Taylor,et al.  Genome-Wide Association , 2007, Diabetes.

[23]  Xavier Estivill,et al.  SNPassoc: an R package to perform whole genome association studies , 2007, Bioinform..

[24]  J. Trent,et al.  A genome-wide scan for naevus count: linkage to CDKN2A and to other chromosome regions , 2007, European Journal of Human Genetics.

[25]  T. Spector,et al.  Genome-wide search for nevus density shows linkage to two melanoma loci on chromosome 9 and identifies a new QTL on 5q31 in an adult twin cohort. , 2006, Human molecular genetics.

[26]  D. Underhill,et al.  Pax3 target gene recognition occurs through distinct modes that are differentially affected by disease-associated mutations. , 2005, Pigment cell research.

[27]  J. Blake,et al.  Pax3 transcripts in melanoblast development , 2005, Development, growth & differentiation.

[28]  S. Gabriel,et al.  Efficiency and power in genetic association studies , 2005, Nature Genetics.

[29]  S. O’Day,et al.  Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. , 2005, Clinical chemistry.

[30]  J. Epstein,et al.  Pax3 functions at a nodal point in melanocyte stem cell differentiation , 2005, Nature.

[31]  J. Barrett,et al.  The effect of sun exposure in determining nevus density in UK adolescent twins. , 2005, The Journal of investigative dermatology.

[32]  P. Boyle,et al.  Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. , 2005, European journal of cancer.

[33]  L. Cannon-Albright,et al.  Longitudinal assessment of the nevus phenotype in a melanoma kindred. , 2004, The Journal of investigative dermatology.

[34]  R. Elashoff,et al.  Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Joaquín Dopazo,et al.  PupaSNP Finder: a web tool for finding SNPs with putative effect at transcriptional level , 2004, Nucleic Acids Res..

[36]  C. Pritchard,et al.  Alternative splicing of Pax3 produces a transcriptionally inactive protein. , 2003, Gene.

[37]  Y. Benjamini,et al.  Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.

[38]  J. Barrett,et al.  Heritability and gene-environment interactions for melanocytic nevus density examined in a U.K. adolescent twin study. , 2001, The Journal of investigative dermatology.

[39]  R. Dummer,et al.  PAX3 is expressed in human melanomas and contributes to tumor cell survival. , 2001, Cancer research.

[40]  M de Lange,et al.  Are Twins and Singletons Comparable? A Study of Disease-related and Lifestyle Characteristics in Adult Women , 2001, Twin Research.

[41]  A. Chompret,et al.  Patterns of familial aggregation of three melanoma risk factors: great number of naevi, light phototype and high degree of sun exposure. , 2000, International journal of epidemiology.

[42]  P Sasieni,et al.  Genetics of risk factors for melanoma: an adult twin study of nevi and freckles. , 2000, Journal of the National Cancer Institute.

[43]  J. A. Bishop,et al.  Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. , 2000, The Journal of investigative dermatology.

[44]  J F Aitken,et al.  A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs. , 1999, American journal of human genetics.

[45]  X. Estivill,et al.  Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene , 1997, Human Genetics.

[46]  B. Assouline,et al.  Familial aggregation of malignant melanoma/dysplastic naevi and tumours of the nervous system: an original syndrome of tumour proneness. , 1997, Annales de genetique.

[47]  J. A. Bishop,et al.  Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. , 1996, British Journal of Cancer.

[48]  G. Edelman,et al.  Pax-3 contains domains for transcription activation and transcription inhibition. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[49]  M A Weinstock,et al.  Epidemiology of melanoma. , 2017, Cancer treatment and research.

[50]  A. Macdonald,et al.  Genetic susceptibility to naevi--a twin study. , 1991, British journal of cancer.

[51]  D McConnell,et al.  Bone Mineral. , 1964, Science.